Heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
AssigneeAddex Pharma SA
InventorsChristelle Boléa, Sylvain Celanire
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel compounds of Formula (I), wherein X1, X2, X3, X4, Y1, Y2, Y3, Y4, M1, M2, M3, Am and Bn are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors—subtype 4 (“mGluR4”) which are useful for the treatment or prevention of central nervous system disorders as well as other disorders modulated by mGluR4 receptors. The invention is also directed to pharmaceutical compositions and the use of such compounds in the manufacture of medicaments, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR4 is involved.
Claims5
A compound according to the general Formula (I),
- a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof and an N-oxide form thereof, wherein:
- A1 radical is selected from the group of hydrogen, halogen, —CN, —CF3, and an optionally substituted radical selected from the group of —(C1-C6)alkyl, aryl;
- n is 1;
- Bn radicals are each independently selected from the group of hydrogen, —CF3, and an optionally substituted radical selected from the group of —(C1-C6)alkyl, and —(C3-C7)cycloalkyl;
- M1 is selected from an optionally substituted 3 to 10 membered ring selected from the group of aryl and heteroaryl;
- and
- M3 is hydrogen.
Dependencies are inferred from the claim text.